Filter search criteria using below inputs
Click on magnifying glass icon to search
Company | Country | Symbol |
---|
Time | Volume | GERN |
---|---|---|
09:32 ET | 51116 | 4.445 |
09:34 ET | 59246 | 4.4 |
09:36 ET | 31952 | 4.38 |
09:38 ET | 5645 | 4.395 |
09:39 ET | 1450 | 4.395 |
09:41 ET | 33264 | 4.395 |
09:43 ET | 253402 | 4.41 |
09:45 ET | 38307 | 4.4 |
09:48 ET | 13688 | 4.395 |
09:50 ET | 13493 | 4.395 |
09:52 ET | 16462 | 4.375 |
09:54 ET | 157441 | 4.36 |
09:56 ET | 18920 | 4.37 |
09:57 ET | 19772 | 4.36 |
09:59 ET | 3876 | 4.3651 |
10:01 ET | 21667 | 4.37 |
10:03 ET | 8094 | 4.375 |
10:06 ET | 7743 | 4.37 |
10:08 ET | 41116 | 4.375 |
10:10 ET | 39681 | 4.36 |
10:12 ET | 73587 | 4.335 |
10:14 ET | 37561 | 4.34 |
10:15 ET | 19585 | 4.33 |
10:17 ET | 3057 | 4.335 |
10:19 ET | 670016 | 4.35 |
10:21 ET | 25282 | 4.3856 |
10:24 ET | 18189 | 4.38 |
10:26 ET | 12993 | 4.395 |
10:28 ET | 19251 | 4.395 |
10:30 ET | 4981 | 4.385 |
10:32 ET | 16583 | 4.385 |
10:33 ET | 17792 | 4.385 |
10:35 ET | 16059 | 4.385 |
10:37 ET | 8262 | 4.385 |
10:39 ET | 7340 | 4.4 |
10:42 ET | 4031 | 4.405 |
10:44 ET | 25172 | 4.415 |
10:46 ET | 152999 | 4.41 |
10:48 ET | 24206 | 4.43 |
10:50 ET | 14300 | 4.435 |
10:51 ET | 2788 | 4.43 |
10:53 ET | 10660 | 4.435 |
10:55 ET | 72091 | 4.42 |
10:57 ET | 25475 | 4.415 |
11:00 ET | 17483 | 4.41 |
11:02 ET | 42014 | 4.42 |
11:04 ET | 600 | 4.425 |
11:06 ET | 14733 | 4.42 |
11:08 ET | 15158 | 4.43 |
11:09 ET | 14586 | 4.43 |
11:11 ET | 10590 | 4.44 |
11:13 ET | 10900 | 4.44 |
11:15 ET | 14667 | 4.45 |
11:18 ET | 33158 | 4.45 |
11:20 ET | 14920 | 4.44 |
11:22 ET | 2000 | 4.44 |
11:24 ET | 19488 | 4.4397 |
11:26 ET | 8357 | 4.435 |
11:27 ET | 2300 | 4.435 |
11:29 ET | 12204 | 4.445 |
11:31 ET | 53961 | 4.44 |
11:33 ET | 1125 | 4.445 |
11:36 ET | 3500 | 4.445 |
11:38 ET | 2730 | 4.445 |
11:40 ET | 34349 | 4.42 |
11:42 ET | 42066 | 4.41 |
11:44 ET | 45781 | 4.41 |
11:45 ET | 8897 | 4.4185 |
11:47 ET | 19145 | 4.4 |
11:49 ET | 15930 | 4.4 |
11:51 ET | 39229 | 4.415 |
11:54 ET | 22210 | 4.411 |
11:56 ET | 17904 | 4.415 |
11:58 ET | 20342 | 4.425 |
12:00 ET | 37487 | 4.42 |
12:02 ET | 5883 | 4.42 |
12:03 ET | 12283 | 4.425 |
12:05 ET | 26330 | 4.43 |
12:07 ET | 12938 | 4.445 |
12:09 ET | 200 | 4.45 |
12:12 ET | 5005 | 4.445 |
12:14 ET | 934 | 4.445 |
12:16 ET | 2425 | 4.44 |
12:18 ET | 300 | 4.45 |
12:20 ET | 16145 | 4.445 |
12:21 ET | 14012 | 4.455 |
12:23 ET | 3932 | 4.455 |
12:25 ET | 41324 | 4.445 |
12:27 ET | 390 | 4.44 |
12:30 ET | 2341 | 4.45 |
12:32 ET | 1700 | 4.445 |
12:34 ET | 22391 | 4.46 |
12:36 ET | 4439 | 4.4607 |
12:38 ET | 1800 | 4.4608 |
12:39 ET | 6924 | 4.4601 |
12:41 ET | 964 | 4.465 |
12:43 ET | 12949 | 4.455 |
12:45 ET | 2413 | 4.45 |
12:48 ET | 1000 | 4.45 |
12:50 ET | 200 | 4.45 |
12:52 ET | 1015 | 4.455 |
12:54 ET | 600 | 4.45 |
12:56 ET | 11005 | 4.46 |
12:57 ET | 2513 | 4.4606 |
12:59 ET | 2016 | 4.46 |
01:01 ET | 600 | 4.465 |
01:03 ET | 5029 | 4.465 |
01:06 ET | 35981 | 4.46 |
01:08 ET | 11038 | 4.46 |
01:10 ET | 17769 | 4.455 |
01:12 ET | 16441 | 4.4606 |
01:14 ET | 2100 | 4.4601 |
01:15 ET | 1418 | 4.47 |
01:17 ET | 26152 | 4.475 |
01:19 ET | 3506 | 4.475 |
01:21 ET | 22647 | 4.485 |
01:24 ET | 77598 | 4.46 |
01:26 ET | 10167 | 4.475 |
01:28 ET | 34157 | 4.47 |
01:30 ET | 6119 | 4.48 |
01:32 ET | 2700 | 4.485 |
01:33 ET | 1352 | 4.485 |
01:35 ET | 7068 | 4.49 |
01:37 ET | 1154 | 4.49 |
01:39 ET | 24283 | 4.48 |
01:42 ET | 5449 | 4.48 |
01:44 ET | 1913 | 4.485 |
01:46 ET | 4350 | 4.485 |
01:48 ET | 19698 | 4.5 |
01:50 ET | 1632 | 4.5 |
01:51 ET | 2575 | 4.495 |
01:53 ET | 837 | 4.495 |
01:55 ET | 6399 | 4.49 |
01:57 ET | 8400 | 4.49 |
02:00 ET | 19806 | 4.48 |
02:02 ET | 400 | 4.485 |
02:04 ET | 15508 | 4.4799 |
02:06 ET | 3124 | 4.475 |
02:08 ET | 1400 | 4.475 |
02:09 ET | 16829 | 4.47 |
02:11 ET | 1536 | 4.475 |
02:13 ET | 11678 | 4.4808 |
02:15 ET | 739 | 4.485 |
02:18 ET | 2553 | 4.485 |
02:20 ET | 25022 | 4.4701 |
02:22 ET | 2113 | 4.475 |
02:24 ET | 32082 | 4.465 |
02:26 ET | 35074 | 4.45 |
02:27 ET | 10498 | 4.44 |
02:29 ET | 800 | 4.445 |
02:31 ET | 4102 | 4.44 |
02:33 ET | 16515 | 4.43 |
02:36 ET | 1300 | 4.435 |
02:38 ET | 11824 | 4.425 |
02:40 ET | 15777 | 4.43 |
02:42 ET | 509 | 4.44 |
02:44 ET | 600 | 4.44 |
02:45 ET | 19362 | 4.445 |
02:47 ET | 29817 | 4.456835 |
02:49 ET | 1540 | 4.46 |
02:51 ET | 18296 | 4.47 |
02:54 ET | 12666 | 4.4606 |
02:56 ET | 4123 | 4.47 |
02:58 ET | 11418 | 4.48 |
03:00 ET | 102297 | 4.52 |
03:02 ET | 25034 | 4.52 |
03:03 ET | 15235 | 4.52 |
03:05 ET | 69286 | 4.53 |
03:07 ET | 56430 | 4.54 |
03:09 ET | 321311 | 4.555 |
03:12 ET | 56438 | 4.54 |
03:14 ET | 39484 | 4.5354 |
03:16 ET | 153016 | 4.545 |
03:18 ET | 8050 | 4.55 |
03:20 ET | 180398 | 4.53 |
03:21 ET | 39848 | 4.54 |
03:23 ET | 591752 | 4.565 |
03:25 ET | 14667 | 4.57 |
03:27 ET | 32739 | 4.59 |
03:30 ET | 21343 | 4.6 |
03:32 ET | 81467 | 4.57 |
03:34 ET | 61746 | 4.565 |
03:36 ET | 21097 | 4.565 |
03:38 ET | 18061 | 4.565 |
03:39 ET | 5480 | 4.565 |
03:41 ET | 49597 | 4.57 |
03:43 ET | 7743 | 4.57 |
03:45 ET | 11178 | 4.57 |
03:48 ET | 102684 | 4.565 |
03:50 ET | 14572 | 4.565 |
03:52 ET | 42142 | 4.58 |
03:54 ET | 63589 | 4.59 |
03:56 ET | 193018 | 4.565 |
03:57 ET | 136186 | 4.575 |
03:59 ET | 2179900 | 4.57 |
Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
---|---|---|---|
Geron Corp | 2.7B | -12.7x | --- |
SpringWorks Therapeutics Inc | 2.8B | -7.3x | --- |
Janux Therapeutics Inc | 2.6B | -50.5x | --- |
Immunitybio Inc | 2.5B | -4.2x | --- |
Agios Pharmaceuticals Inc | 2.7B | -7.0x | --- |
Celldex Therapeutics Inc | 2.9B | -12.1x | --- |
Geron Corporation is a late-stage clinical biopharmaceutical company developing investigational first-in-class telomerase inhibitor, imetelstat, to treat hematologic malignancies. The Company is engaged in the development of therapeutic products for oncology. Its lead indication for imetelstat is in Low or Intermediate-1 risk myelodysplastic syndromes. It is developing imetelstat for the treatment of several myeloid hematologic malignancies, including a Phase 3 clinical trial, named IMpactMF, in relapsed/refractory myelofibrosis (MF) with overall survival as the primary endpoint, that is enrolling patients. It is also conducting a Phase 1 combination therapy clinical trial, named IMproveMF, in first-line Intermediate-1, Intermediate-2 or High-Risk myelofibrosis, or frontline MF, that is enrolling patients and imetelstat is being studied in an investigator-led Phase 2 clinical trial, named IMpress, in Intermediate-2 or High-Risk myelodysplastic syndromes and acute myeloid leukemia.
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $2.7B |
---|---|
Revenue (TTM) | $1.4M |
Shares Outstanding | 602.8M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 0.50 |
EPS | $-0.36 |
Book Value | $0.46 |
P/E Ratio | -12.7x |
Price/Sales (TTM) | 1,980.1 |
Price/Cash Flow (TTM) | --- |
Operating Margin | -16,559.94% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.